The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global endoscope reprocessing market reached a value of US$ 1.85 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.93 Billion by 2027, exhibiting a CAGR of 7.96% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Endoscopes are used in the early detection, diagnosis, and treatment of malignant gastrointestinal (GI) diseases. However, the risk of infection transmission associated with endoscopes is usually high due to their complex structure and diverse use in medical procedures. As a result, health agencies of several countries have implemented strict endoscope reprocessing protocols to improve safety and reduce the spread of infections. These protocols ensure that endoscopes undergo various steps of meticulous cleaning and disinfection before being reused on patients. Moreover, several manufacturers are introducing automated endoscope reprocessors (AERs) for consistent, accurate, and cost-effective operation. AERs help kill microorganisms on reusable endoscopes by exposing their outside surfaces and interior channels to high-level disinfectant or liquid chemical sterilant solutions.
The coronavirus disease (COVID-19) outbreak has led to an increase in the number of people experiencing various GI symptoms, such as nausea, vomiting, and diarrhea. This, along with the mortality risk associated with GI diseases, is positively influencing the need for endoscopy procedures across the globe to improve patient safety. Apart from this, the growing pediatric population, which is relatively more vulnerable to targeted diseases, is driving the demand for flexible endoscopes to diagnose and treat cancer and GI disorders. In addition, endoscopy devices are used to investigate unusual symptoms like dysphagia, diarrhea, weight loss, heartburn, and stool blood, which is propelling the adoption of endoscope reprocessing to prevent the risk of infection. Moreover, health agencies are conducting facility-level training programs to assist healthcare institutions in achieving a reliable, high-quality reprocessing of endoscopes. This, in confluence with the increasing focus on improving reprocessing guidelines, is anticipated to fuel the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global endoscope reprocessing market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, process and end user.
Breakup by Product:
Breakup by Process:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Advanced Sterilization Products (ASP) (Fortive Corporation), ARC Healthcare Solutions Inc., Belimed AG (Metall Zug AG), BES Rehab Ltd, Custom Ultrasonics Inc., Ecolab Inc., ENDO-TECHNIK W. Griesat GmbH (Albyn Medical S.L.), Getinge AB, HOYA Corporation, Metrex Research LLC, Olympus Corporation, Shinva Medical Instrument Co. Ltd., Steelco S.p.A. (Miele) and Steris plc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Process, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Advanced Sterilization Products (ASP) (Fortive Corporation), ARC Healthcare Solutions Inc., Belimed AG (Metall Zug AG), BES Rehab Ltd, Custom Ultrasonics Inc., Ecolab Inc., ENDO-TECHNIK W. Griesat GmbH (Albyn Medical S.L.), Getinge AB, HOYA Corporation, Metrex Research LLC, Olympus Corporation, Shinva Medical Instrument Co. Ltd., Steelco S.p.A. (Miele) and Steris plc|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at